EXACT Sciences (EXAS) Scheduled to Post Earnings on Thursday

Share on StockTwits

EXACT Sciences (NASDAQ:EXAS) will issue its quarterly earnings data after the market closes on Thursday, February 21st. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

EXACT Sciences stock opened at $89.27 on Thursday. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $90.94. The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. The firm has a market capitalization of $11.03 billion, a price-to-earnings ratio of -90.17 and a beta of 1.83.

In other news, insider Kevin T. Conroy sold 304,397 shares of EXACT Sciences stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $81.27, for a total transaction of $24,738,344.19. Following the sale, the insider now owns 1,190,408 shares in the company, valued at $96,744,458.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jeffrey Thomas Elliott sold 90,909 shares of EXACT Sciences stock in a transaction dated Thursday, January 24th. The stock was sold at an average price of $78.90, for a total value of $7,172,720.10. Following the sale, the chief financial officer now owns 124,120 shares in the company, valued at approximately $9,793,068. The disclosure for this sale can be found here. Insiders have sold 396,887 shares of company stock worth $32,010,272 in the last quarter. Insiders own 3.20% of the company’s stock.

EXAS has been the topic of a number of analyst reports. Jefferies Financial Group raised their price target on EXACT Sciences from $74.00 to $84.00 and gave the company a “buy” rating in a research note on Wednesday, October 31st. William Blair restated an “outperform” rating on shares of EXACT Sciences in a research note on Monday, January 7th. UBS Group raised their price target on EXACT Sciences from $100.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, January 28th. Canaccord Genuity raised their price target on EXACT Sciences from $87.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, January 14th. Finally, TheStreet upgraded EXACT Sciences from a “d” rating to a “c-” rating in a research note on Tuesday, November 6th. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. EXACT Sciences currently has a consensus rating of “Buy” and an average target price of $90.73.

COPYRIGHT VIOLATION WARNING: “EXACT Sciences (EXAS) Scheduled to Post Earnings on Thursday” was originally posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://baseballnewssource.com/2019/02/14/exact-sciences-exas-scheduled-to-post-earnings-on-thursday/3214523.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Article: Market Capitalization in the Stock Market

Earnings History for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.